REFERENCES
1. Carabelli A M, Peacock T P, Thorne L G, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol . 2023;21(3):162-177.
2. Shrestha L B, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev Med Virol . 2022;32(5):e2381.
3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2023; Available online: https://covid19.who.int/ (accessed on 2 November 2023).
4. Wang W C, Sayedahmed E E, Sambhara S, et al. Progress towards the Development of a Universal Influenza Vaccine. Viruses . 2022;14(8).
5. Swets M C, Russell C D, Harrison E M, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, o adenoviruses. Lancet . 2022;399(10334):1463-1464.
6. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med . 2022;28(11):2398-2405.
7. Su S, Liu Z, Jiang S. Double insult: flu bug enhances SARS-CoV-2 infectivity. Cell Res . 2021;31(5):491-492.
8. Ye Q, Wu M, Zhou C, et al. Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines . 2022;7(1):84.
9. Tripp R A. Understanding immunity to influenza: implications for future vaccine development. Expert Rev Vaccines . 2023;22(1):871-875.
10. Liu Q, Qin C, Liu M, et al. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty . 2021;10(1):132.
11. Mohamed K, Rzymski P, Islam M S, et al. COVID-19 vaccinations: The unknowns, challenges, and hopes. J Med Virol . 2022;94(4):1336-1349.
12. Chaparian R R, Harding A T, Hamele C E, et al. A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. J Virol . 2022;96(15):e68922.
13. Chen J, Wang P, Yuan L, et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci Bull (Beijing) . 2022;67(13):1372-1387.
14. Shi R, Zeng J, Xu L, et al. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. EBioMedicine . 2022;85:104297.
15. Wang Z, Li Z, Shi W, et al. A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus. Sci Adv . 2023;9(25):o4100.
16. Cao K, Wang X, Peng H, et al. A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice. J Virol . 2022;96(4):e157821.
17. Ao Z, Ouyang M J, Olukitibi T A, et al. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection. J Virol . 2022;96(18):e133722.
18. Zhang N, Ji Q, Liu Z, et al. Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant. Viruses . 2022;14(3).
19. Liu Z, Xu W, Chen Z, et al. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. Protein Cell . 2022;13(9):655-675.
20. Zhou Y, Liu Z, Li S, et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep . 2021;34(5):108699.
21. Cheng Y, Ma J, Wang H, et al. Co-infection of influenza A virus and SARS-CoV-2: A retrospective cohort study. J Med Virol . 2021;93(5):2947-2954.